Skip to main content
SpringerLink
Log in

Dabrafenib: First Global Approval

  • R&D Insight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Dabrafenib (Tafinlar®), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline’s research programme for the discovery of selective inhibitors of mutant BRAF kinase activity, for the treatment of solid tumours; mutations in the BRAF gene are associated with increased growth and proliferation of cancer cells. GlaxoSmithKline has focused the development of dabrafenib on the treatment of malignant melanoma, as BRAF mutations are present in 50 % of these cancers. Dabrafenib is approved in the US as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation, and has received a positive opinion in the EU in this indication. Submissions have also been made in the US and the EU for the use of dabrafenib in combination with trametinib for the treatment of metastatic melanoma with a BRAF V600E/K mutation. Global phase III development of dabrafenib as a monotherapy and as a combination therapy is ongoing in the treatment of malignant melanoma. Phase II development is ongoing for the treatment of malignant melanoma that has metastasised to the brain, and for colorectal and non-small cell lung cancers. Dabrafenib is intended to treat the patient population with a BRAF V600E/K mutation. GlaxoSmithKline’s dabrafenib application in the US included the treatment of this population as detected by a US FDA-approved test. GlaxoSmithKline, in collaboration with bioMérieux and Response Genetics, has developed a molecular theranostic test to identify BRAF V600E/K mutations. Pre-Market approval of the test has been granted by the FDA. This article summarises the milestones in the development of dabrafenib leading to this first approval as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. Ann Pharmacother. 2013;47(4):519–26.

    Article  PubMed  Google Scholar 

  2. Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013;14(2):280–92.

    Article  PubMed  Google Scholar 

  3. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60–9.

    Article  PubMed  CAS  Google Scholar 

  4. Laquerre S, Arnone M, Moss K, et al. A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-Raf V600E mutation. [abstract no. B88]. 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Nov 15 2009.

  5. Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front. 2013;3:54.

    Google Scholar 

  6. GlaxoSmithKline. Tafinlar® (dabrafenib capsules): US prescribing information. 2013. http://us.gsk.com/products/assets/us_tafinlar.pdf. Accessed Jun 13 2013.

  7. GlaxoSmithKline. Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar(Rm) (dabrafenib) capsules and the first MEK-inhibitor Mekinist(Tm) (trametinib) tablets, approved by FDA as single-agent therapies [media release]. May 29 2013. http://www.gsk.com.

  8. GlaxoSmithKline. Regulatory Update - GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib) [media release]. Jun 28 2013. http://www.gsk.com.

  9. GlaxoSmithKline. Regulatory Update - GSK announces submissions in the EU and US for dabrafenib and trametinib [media release]. Aug 3 2012. http://www.gsk.com.

  10. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.

    Article  PubMed  CAS  Google Scholar 

  11. GlaxoSmithKline. GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma [media release]. Feb 7 2013. http://www.gsk.com.

  12. GlaxoSmithKline. Regulatory update – GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma [media release]. Jul 09 2013. http://www.gsk.com.

  13. Gentilcore G, Madonna G, Mozzillo N, et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer. 2013;13:17.

    Article  PubMed  CAS  Google Scholar 

  14. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893–901.

    Article  PubMed  CAS  Google Scholar 

  15. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–31.

    Article  PubMed  CAS  Google Scholar 

  16. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3 K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909–20.

    Article  PubMed  CAS  Google Scholar 

  17. Nebot N, Ma B, Haney P, et al. Exposure-response modeling of the effect of dabrafenib, a braf inhibitor, on objective response rate (ORR) in patients with braf V600 mutation positive melanoma [abstract no. PII-37]. Clin Pharmacol Ther. 2013;93(Suppl. 1):S65–6.

    Google Scholar 

  18. Nebot N, Chiu JS, Ma B, et al. Exposure-response analysis of the effect of dabrafenib, a braf inhibitor, on tumor size in patients with V600 braf mutation positive melanoma [abstract no. OII-B-1]. Clin Pharmacol Ther. 2013;93(Suppl. 1):S51.

    Google Scholar 

  19. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    Article  PubMed  CAS  Google Scholar 

  20. Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer. 2013;49(5):1073–9.

    Article  PubMed  CAS  Google Scholar 

  21. Long GV, Ascierto PA, Grob JJ, et al. Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436) [abstract no. 8518]. J Clin Oncol. 2012;30(15 Suppl.).

  22. Nathanson KL, Martin A, Letrero R, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436) [abstract no. 8501]. J Clin Oncol. 2011;29(15 Suppl.).

  23. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95.

    Article  PubMed  CAS  Google Scholar 

  24. Azer M, Menzies A, Haydu L, et al. Patterns of progression in patients with V600 brafmutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436). Asia Pac J Clin Oncol. 2012;8(Suppl. 2):48.

    Google Scholar 

  25. Weber JS, Flaherty KT, Infante JR, et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma [abstract no. 8510]. J Clin Oncol. 2012;30(15 Suppl.).

  26. Corcoran RB, Falchook GS, Infante JR, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) [abstract no. 3528]. J Clin Oncol. 2012;30(15 Suppl.).

  27. Response Genetics Inc. Response Genetics Signs Agreement with GlaxoSmithKline to provide proprietary BRAF mutational analysis technology [media release]. May 11 2013. http://www.responsegenetics.com.

Download references

Author information

Authors and Affiliations

  1. Adis R & D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Anita D. Ballantyne

  2. Adis, Auckland, New Zealand

    Karly P. Garnock-Jones

Authors
  1. Anita D. Ballantyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anita D. Ballantyne.

Additional information

This profile has been extracted and modified from the Adis R&D Insight drug pipeline database. Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ballantyne, A.D., Garnock-Jones, K.P. Dabrafenib: First Global Approval. Drugs 73, 1367–1376 (2013). https://doi.org/10.1007/s40265-013-0095-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0095-2

Keywords

Search

Navigation